The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 145-page report you will receive 100 charts – all unavailable elsewhere.
The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Epilepsy Drugs Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
– First-generation Drugs
– Second-generation Drugs
– Third-generation Drugs
– Others
• This report also discusses the leading anti-epilepsy drugs:
– Vimpat
– Keppra
– Briviact
– Lamictal
– Potiga/Trobalt
– Lyrica
– Neurontin
• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– Japan
– EU5
– BRIC
– RoW
• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK
• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market
• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy
• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market
• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016
Visiongain’s study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.
Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Introduction to Epilepsy
2.1 What are Seizures?
2.2 What is status epilepticus?
2.2.1 Types of Seizures
2.2.1.1 Onset of Seizures
2.2.1.2 Level of Awareness
2.2.1.3 Presence or Absence of Motor Symptoms
2.3 Epilepsy Syndrome
2.4 What Are the Risk Factors for Epilepsy?
2.4.1 Age
2.4.2 Head injuries
2.4.3 Family History
2.4.4 Childhood Seizures
2.4.5 Infections
2.4.6 Dementia and Vascular Diseases
2.4.7 Administration of Drugs
2.5 What Are the Various Complications Associated with Epilepsy?
2.5.1 Increased Likelihood of Road Accidents
2.5.2 Increased Risk of Falls and Drowning while Swimming
2.5.3 Complications during Pregnancy
2.5.4 Impairment of Mental Health and Social Stigma Associated with the Disease
2.5.5 Status Epilepticus
2.5.6 Sudden Unexplained Death in Epilepsy (SUDEP)
2.6 Diagnosis of Epilepsy
2.6.1.1 Electroencephalogram (EEG)
2.6.1.2 Neuroimaging
2.6.1.3 Other Tests
2.6.1.4 Neuropsychological Assessment
2.7 Epidemiology of Epilepsy
2.7.1 Incidence
2.7.2 Prevalence
2.7.2.1 Epidemiology by Country
2.7.2.2 Historical Prevalence in G7 Markets
2.7.2.3 Forecast of Epilepsy in G7 Markets 2016-2027
2.8 Humanistic and Economic Burden
2.8.1 Mortality
2.8.1.1 Mortality in the US
2.8.1.2 Mortality in the UK
2.8.2 HRQoL
2.8.3 Economic Impact
2.8.3.1 Direct and Indirect Costs of Caregiving
2.9 Epilepsy: Treatment
2.9.1 Pharmacotherapy
2.9.2 Psychological Interventions
2.9.3 Dietary Modifications
2.9.4 Vagus Nerve Stimulation (VNS)
2.9.5 Epilepsy Surgery
2.9.6 Deep Brain Stimulation (DBS)
2.9.7 Responsive Neurostimulation System (RNS)
3. Introduction to the Anti-Epilepsy Drugs Market
3.1 Market Definition and Scope
3.2 Market Drivers, Challenges, and Trends
3.2.1 Market Drivers
3.2.1.1 Unmet Medical Need
3.2.1.2 Increase in Patient Population
3.2.1.3 Research Funding and Awareness
3.2.2 Market Challenges
3.2.2.1 Market Entry of Generic Drugs
3.2.2.2 Social Stigma Associated with Neurological Disorders
3.2.3 Market Trends
3.2.3.1 Reformulation and Indication Expansion
3.2.3.2 Emergence of New-generation of AEDs
4. Global Anti-Epilepsy Drugs Market 2016
4.1 Global Anti-Epilepsy Drugs Market Forecast 2017-2027
4.1 Market Segmentation by Generation of Drugs
4.1.1 Global Anti-Epilepsy Drugs Submarkets Forecast 2017-2027
4.1.1.1 Global Anti-Epilepsy First Generation Drugs Market Forecast 2017-2027
4.1.1.2 Global Anti-Epilepsy Second Generation Drugs Market Forecast 2017-2027
4.1.1.3 Global Anti-Epilepsy Third Generation Drugs Market Forecast 2017-2027
4.1.1.4 Global Anti-Epilepsy Other Drugs Market Forecast 2017-2027
5. Global Anti-Epilepsy Drugs - Market Players
5.1 Historical Market Share
5.2 Current Market Leaders
5.2.1 UCB
5.2.1.1 Vimpat
5.2.1.2 Keppra
5.2.1.3 Briviact
5.2.2 GlaxoSmithKline
5.2.2.1 Lamictal
5.2.2.2 Potiga / Trobalt
5.2.3 Pfizer
5.2.3.1 Lyrica
5.2.3.2 Neurontin
6. Leading National Markets Forecast 2017-2027
6.1 Geographical Breakdown of Global Anti-Epilepsy Drugs Market, 2016
6.2 Anti-Epilepsy Drugs Market Forecast by Region 2017-2027
6.3 Anti-Epilepsy Drugs Market in the US, 2016
6.3.1 Market Forecast of the US, 2017-2027
6.4 Anti-Epilepsy Drugs Market in EU5, 2016
6.4.1 Market Forecast of EU5, 2017-2027
6.5 Anti-Epilepsy Drugs Market in the BRIC, 2016
6.5.1 Market Forecast of the BRIC, 2017-2027
6.6 Anti-Epilepsy Drugs Market in Japan, 2016
6.6.1 Market Forecast of the Japan, 2017-2027
6.7 Anti-Epilepsy Drugs Market in RoW, 2016
6.7.1 Market Forecast of the RoW, 2017-2027
7. Pricing and Reimbursement Overview
7.1 NICE
7.2 SMC
7.3 HAS
7.4 Canada
7.5 Italy
7.6 United States
7.7 Australia
7.8 G-BA/IQWIG
8. Active Pipeline Molecules
8.1 Overall Pipeline Status and Promising Candidates
8.1.1 Everolimus
8.1.2 Lyrica Controlled-release
8.1.3 Briviact
8.1.4 Vimpat
8.1.5 E2007
8.1.6 SAGE-547
8.1.7 Epidiolex
8.1.8 Cenobamate
8.1.9 ZX008
8.1.10 Ganaxolone
8.1.11 Immunoglobulin, normal (human)
8.1.12 USL261
8.1.13 Alprazolam
8.1.14 Ataluren
8.1.15 GWP42006
8.1.16 PF-062372865
8.1.17 UCB-0942 and UCB-3491
8.1.18 BGG-492
8.1.19 PRX00023
8.2 Novel Mechanism of Action
9. Conclusions
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %, Cumulative)
Table 2.1 Type of Focal Seizures
Table 2.2 Type of Unknown-onset Seizures
Table 2.3 Prevalence of Epilepsy, all ages, all types, rates per 1,000 population per year
Table 2.4 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
Table 2.5 Forecast of Diagnosed Prevalence of Epilepsy in G7 Markets: AGR (%), CAGR (%), 2016-2027
Table 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
Table 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
Table 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
Table 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
Table 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
Table 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
Table 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
Table 2.13 Healthcare Utilization Rates by Caregivers of Individuals Suffering from Epilepsy vs General Population
Table 2.14 Direct and Indirect Costs for the General Population and Caregivers of Persons with Epilepsy (in US$)
Table 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.2 List of some of the Approved AEDs
Table 4.3 Global Anti-Epilepsy Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2016
Table 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.5 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
Table 4.6 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.7 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.8 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.9 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.1 Product Portfolio of UCB
Table 5.2 Vimpat Key Milestones
Table 5.3 Keppra / Keppra XR Key Milestones
Table 5.4 Briviact Key Milestones
Table 5.5 Product Portfolio of Pfizer
Table 6.1 Anti-Epilepsy Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 6.2 Anti-Epilepsy Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027
Table 6.3 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.4 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.5 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.6 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.7 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 8.1 Active Pipeline Molecules under Development for Treating Epilepsy
List of Figures
Figure 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.1 Types of Generalized Seizures
Figure 2.2 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
Figure 2.3 Diagnosed Prevalence (%) of Epilepsy in G7 Markets, 2016
Figure 2. 4 Historical Prevalence of Epilepsy in G7 Markets: CAGR (%), 2011-2015
Figure 2.5. Historical Diagnosed Prevalence of Epilepsy in G7 Markets: Share (%) of Absolute cases, 2011-2015
Figure 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
Figure 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
Figure 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
Figure 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
Figure 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
Figure 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
Figure 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
Figure 2.13 Epilepsy and Status Epilepticus Related Deaths in the US, 2015
Figure 2.14 Epilepsy and Status Epilepticus Related Deaths in the US, 2013 – 2015
Figure 2.15 Epilepsy and Status Epilepticus Related Deaths in the UK, 2015
Figure 2.16 Epilepsy Related Deaths in the UK, 2013 – 2015
Figure 2.17 Percentage of Adults with and Without Epilepsy Who Have Difficulty Getting Health Care
Figure 2.18Treatment Algorithm of Epilepsy using Pharmacotherapies
Figure 2.19 Pharmacotherapy for Seizures
Figure 2.20Treatment Algorithm of Status Epilepticus using Pharmacotherapies
Figure 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.2: Epilepsy Market Segmentation by Generation of Drugs
Figure 4.3 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), 2016
Figure 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Market Share (%), 2016
Figure 4.5 Global Anti-Epilepsy Drugs Market by Generation of Drugs 2016-2027: Revenue ($m), Global AGR (%)
Figure 4.6 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), CAGR (%), 2016 & 2027
Figure 4.7 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
Figure 4.8 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.9 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.10 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.11 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 5.1 Market Share of AEDs, in 2008
Figure 5.2 Vimpat Revenue 2011-2016 (US$ million)
Figure 5.3 Vimpat Sales by Geographical Segmentation, 2016
Figure 5.4 Vimpat Forecasted Revenue 2017-2022 (US$ million)
Figure 5.5 Market Growth of Vimpat in the US and EU (in 2016)
Figure 5.6 Keppra/Keppra XR Revenue 2011-2016 (US$ million)
Figure 5.7 Keppra/Keppra XR Sales by Geographical Segmentation 2016
Figure 5.8 Keppra/Keppra XR Forecasted Revenue 2017-2022 (US$ million)
Figure 5.9 Market Growth of Keppra/Keppra XR in the US and EU (in 2016)
Figure 5.10 Briviact Sales by Geographical Segmentation 2016
Figure 5.11 Briviact Forecasted Revenue 2017-2022 (US$ million)
Figure 5.12 Lamictal Revenue 2011-2016 (US$ million)
Figure 5.13 Lamictal Sales by Geographical Segmentation 2016
Figure 5.14 Lyrica Revenue 2011-2016 (US$ million)
Figure 5.15 Neurontin Revenue 2011-2016 (US$ million)
Figure 6.1 Anti-Epilepsy Drugs Market Segmentation by Region/Country
Figure 6.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)
Figure 6.3 Anti-Epilepsy Drugs Market by Region: Market Share 2016 (%)
Figure 6.4 Global Anti-Epilepsy Drugs Market in the US: Market Share (%), 2016
Figure 6.5 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)
Figure 6.6 Anti-Epilepsy Drugs Market in the EU5: Market Share (%), 2016
Figure 6.7 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%)
Figure 6.8 Anti-Epilepsy Drugs Market in BRIC: Market Share (%), 2016
Figure 6.9 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%)
Figure 6.10 Anti-Epilepsy Drugs Market in Japan: Market Share (%), 2016
Figure 6.11 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%)
Figure 6.12 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%)
Figure 8.1 Share of Pipeline Molecules by Phase of Development
Figure 8.2 Status of Patent Protection of Afinitor (excludes patent on cancer indications
Figure 9.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 9.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)
Abide Therapeutics
Advicenne Pharma SA
Alexza Pharmaceuticals
American Epilepsy Society
Argentum Pharmaceuticals
Biscayne Neurotherapeutics
Canadian Agency for Drugs and Technologies in Health (CADTH)
Catalyst Pharmaceuticals
Centers for Disease Control (CDC)
Eisai
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GlaxoSmithKline (GSK)
Grifols S.A.
GW Pharmaceuticals
International League Against Epilepsy (ILAE)
Italian Medicines Agency (AIFA)
Janssen Pharmaceuticals
Japanese Ministry of Health, Labour and Welfare (MHLW)
Marinus Pharmaceuticals
National Institute of Neurological Disorders and Stroke
Novartis
Otsuka Pharmaceuticals
Pfizer
Pharmaceutical Benefits Advisory Committee (PBAC)
Proximagen
PTC Therapeutics
Roche
Sage Therapeutics
Sanofi
Scottish Medicines Consortium (SMC)
SK Biopharmaceuticals
Takeda
The National Institute for Health and Care Excellence (NICE)
UCB
Upsher-Smith Laboratories
World Health Organization (WHO)
Zogenix
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
